Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built a pipeline and set of enabling technologies that could enable a steep period of value creation based on RNAi. The team then analyzes the $2 billion deal between Synnovation and Novartis for a pan-mutant-selective PI3Kα inhibitor. The analysts also assess where AI is integrating into the biotech venture funnel and provide insights into ultra-rare disease advocacy , FDA’s search for a successor to CBER Director Vinay Prasad, and the Trump administration’s most-favored nation (MFN) drug pricing policy. View full story: 00:00 - Introduction 01:14 - Bio€quity Europe 05:33 - Arrowhead 16:49 - Synnovation Novartis 20:00 - AI in Biotech Venture 27:07 - Rare Disease Advocacy 31:22 - MFN Pricing Policy To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

You can listen to Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN is an episode from BioCentury This Week by BioCentury.

This episode is 33:59 long.

This episode was published on Mar 24, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.